West Pharmaceutical Non-GAAP EPS of $2.11 beats by $0.18, revenue of $753.8M in-line

• West Pharmaceutical press release (NYSE:WST): Q2 Non-GAAP EPS of $2.11 beats by $0.18.
• Revenue of $753.8M (-2.3% Y/Y) in-line.
• The Company is raising full-year 2023 net sales guidance to a new range of $2.970 billion to $2.995 billion, compared to a prior range of $2.965 billion to $2.990 billion.
• The Company is raising full-year 2023 adjusted-diluted EPS guidance to a new range of $7.65 to $7.80, compared to a prior range of $7.50 to $7.65.